

79271_Auto_Edited-check.docx

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 79271

Manuscript Type: CASE REPORT

Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature

Lee CL *et al.* Institutional case series of advanced PACC

Abstract

BACKGROUND

Pancreatic acinar cell carcinoma (PACC) is a rare tumor. Up to 45% of PACCs have alterations in the DNA damage repair pathway and 23% harbor rearrangements in the *BRAF* or *RAF1* genes. We present a PACC case with a germline *BRCA2* likely pathogenic variant (LPV) to highlight the impact of genomic testing on treatment decisions and patient outcomes. In our larger case series, we provide clinic-based information on additional 10 PACC patients treated in our center.

CASE SUMMARY

A 70-year-old male was diagnosed with advanced PACC. At presentation, he was cachectic with severe arthralgia despite prednisolone and a skin rash that was later confirmed to be panniculitis. He was treated with modified FOLFIRINOX (mFFX) with the knowledge of the germline *BRCA2* LPV. Following 11 cycles of mFFX, a computed tomography scan demonstrated significant tumor response in the pancreatic primary and hepatic metastases, totaling 70% from baseline as per Response Evaluation Criteria in Solid Tumors. Resolution of the skin panniculitis was also noted. We identified two additional PACCs with druggable targets in our case series. Our data contribute to practical evidence for the value of germline and somatic profiling in the management of rare diseases like PACC.

CONCLUSION

This patient and others in our larger case series highlight the importance of genomic testing in PACC with potential utility in personalized treatment.

Key Words: Pancreatic acinar carcinoma; *BRCA*; Polyadenosine diphosphate-ribose polymerase inhibitor; Case report

Lee CL, Holter S, Borgida A, Dodd A, Ramotar S, Grant R, Wasson K, Elimova E, Jang RW, Moore M, Kim TK, Khalili K, Moulton C, Gallinger S, O'Kane GM, Knox JJ. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature. *World J Gastroenterol* 2022; In press

Core Tip: Pancreatic acinar cell carcinoma (PACC) is a rare tumor with distinct molecular features and a relatively high proportion of targetable mutations. In this article, we describe a case report of PACC with a germline *BRCA2* likely pathogenic variant, with a series of 10 additional cases, along with an in-depth look at the patients' therapeutic details. We aim to outline the advantages of genomic analysis and its outcome regarding treatment selection in this tumor type.

INTRODUCTION

Pancreatic acinar cell carcinoma (PACC) is a rare subtype of pancreatic cancer, accounting for 1%-2% of exocrine pancreatic neoplasms^[1]. While there is some clinical and genotype difference, patients with PACC and pancreatic ductal adenocarcinoma (PDAC) are often treated as one disease entity. Evolving data has increased our understanding of this rare tumor's biology, treatment, and prognosis. Due to the disease's rarity, most data about PACC are limited to reviews, case reports, and case series. The tumor biology of PACC is not well characterized due to the lack of tissue availability for large-scale molecular analysis. Intriguingly, data obtained in recent years have indicated that PACC has a distinctive mutational landscape^[2-4]. There is increasing interest in this area, particularly regarding the homologous repair deficiency (HRD) signature in PACC. Chmielecki *et al*^[2] reported up to 45% deficiency of the DNA damage repair (DDR) pathway genes in the study population. Oncogenic therapeutic targets including *BRAF* rearrangements and mismatch repair genes have proven elusive in a significant proportion of PACCs, and lack of tumor profiling probably contributes to low reporting^[3,4].

Here, we present a PACC case to emphasize the clinical application of genomic profiling in the context of precision medicine for better patient outcomes. Although this patient was very unwell at the presentation, raising the question of suitability for modified FOLFIRINOX (mFFX), the knowledge of the *BRCA2* likely pathogenic variant (LPV) as predictive for mFFX sensitivity guided our decision to use this regime. In the case series section, we describe the clinical characteristics, therapeutic outcome and mutational signatures of additional 10 patients with PACC treated in our center. As proof of concept, we describe the immediate clinical impact for the patients with distinct genomic alterations that have been associated with sensitivity to specific chemotherapeutic or targeted agents.

CASE PRESENTATION

Chief complaints

The patient was a 70 mo smoker with recurrent lower limb joint pain and was generally unwell for the previous year.

History of present illness

He presented to a rheumatology service with joint pain, which was diagnosed as gout and treated with short courses of prednisolone; however, during the steroid treatment, he also experienced central abdominal discomfort, reduced appetite, and 10 kg weight loss. He had progressive lower joint pain with tender, warm skin nodules, which restricted mobility.

History of past illness

He had encephalitis and asthma as a child.

Personal and family history

He had a history of transitional cell carcinoma of the renal pelvis at age 46 for which he underwent a left total nephrectomy and a non-small cell lung adenocarcinoma at age 51, which was treated by lung resection. His mother died of ovarian cancer at age 72.

Physical examination

Physical examination revealed a cachectic man with a palpable liver edge and ill-defined widespread erythematous subcutaneous nodules on bilateral lower limbs (Figure 1A). Eastern Cooperative Oncology Group performance status (PS) was 2.

Laboratory examinations

Initial blood tests demonstrated lipase > 6000 U/dL, elevated transaminase levels [alanine aminotransferase (ALT) 68 U/L and ALT 58 U/L], total bilirubin 6 µmol/L, albumin 28 g/L and creatinine 120 µmol/L (epidermal growth factor receptor (eGFR) 52 mL/min). Tumor markers were: normal carbohydrate antigen 19-9 (CA19-9) 28 kU/L and raised alpha-fetoprotein 58 µg/L.

Imaging examinations

Initial blood tests demonstrated lipase > 6000 U/dL, elevated transaminase levels (ALT 68 U/L and ALT 58 U/L), total bilirubin 6 µmol/L, albumin 28 g/L and creatinine 120 µmol/L (eGFR 52 mL/min). Tumor markers were: normal CA19-9 28 kU/L and raised alpha-fetoprotein 58 µg/L.

FURTHER DIAGNOSTIC WORK-UP

The patient underwent a liver biopsy that confirmed a poorly differentiated carcinoma staining positive for keratin 7, CAM5.2, claudin 4, glypican 3, and A1AT. Negative markers included keratin 20, arginase 1, hepPar1, synaptophysin, chromogranin, CD56, and TTF1. The tumor was mismatch repair proficient. An additional skin biopsy of one of the subcutaneous nodules confirmed pancreatic lobular panniculitis. Germline testing identified a *BRCA2* LPV (c.4356delinsCA, p. Gln1452Hisfs*8).

FINAL DIAGNOSIS

These findings were compatible with PACC with panniculitis, hepatic metastases, and indeterminate bony involvement. Histology revealed no concurrent existence of ductal adenocarcinoma, neuroendocrine or mixed tumor of the pancreas.

TREATMENT

The initial plan was to treat the patient with Gemcitabine plus Nab-paclitaxel (GnP) in consideration of his poor PS. However, this decision was changed to the mFFX regimen following the documentation of the germline *BRCA2* LPV. mFFX was administered every 2-wk with an additional 20% dose reduction of Oxaliplatin and Irinotecan (Oxaliplatin 65 mg/m², Irinotecan 120 mg/m², Fluorouracil 4200 mg/m² and Folinic acid 400 mg/m²). The chemotherapy calculations were based on a body surface area of 1.77 m².

OUTCOME AND FOLLOW-UP

After the first cycle of mFFX, the patient was hospitalized due to fever, confusion, and worsening polyarthrititis. A full septic screen revealed no clear infectious etiology. Computed tomography (CT) brain showed no brain abnormality. X-rays of several joint areas including sacroiliac joints showed no radiographic evidence of osteomyelitis or septic arthritis. A left knee joint aspiration revealed an inflammatory synovial fluid with elevated white blood cell count, but no growth of infectious organisms and negative for crystal arthropathy. Rheumatoid factor and anti-cyclic citrullinated peptide levels were negative. The rheumatology team believed the patient's inflammatory seronegative arthritis was paraneoplastic in nature. The patient also displayed clinical adverse events consistent with steroid-induced psychosis, due to the concurrent prednisolone and dexamethasone use. He was started on Naproxen with a tapering dose of prednisolone (from 15 mg daily). His condition improved within a week time and chemotherapy was resumed. Two months after starting mFFX, CT evaluation (post 4 cycles of

chemotherapy) showed a 56% partial response based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The patient had a marked improvement in symptomatology and panniculitis. His PS also improved to 0. He continued to tolerate mFFX with grade 1 peripheral sensory neuropathy of hands and feet. Another CT (post 8 cycles of chemotherapy) showed further tumor shrinkage in the primary tumor and hepatic metastases. The sclerotic bone lesion was unchanged in the interval. As the patient was getting deepening partial response and tolerating mFFX, the chemotherapy was repeated for a total of 11 cycles. A CT imaging at that time point showed further tumor regression in the pancreatic tumor and the hepatic metastases, totaling a 70% decrease from baseline (Figure 2B). The biochemical response was also seen with a CA19-9 level of 17 kU/L.

After 11 cycles of mFFX, we decided to stop chemotherapy due to the accumulative neurotoxicity. Considering the germline *BRCA2* LPV, we elected a therapeutic switch to Olaparib, a polyadenosine diphosphate-ribose polymerase inhibitor (PARPi), as maintenance therapy. He was started on Olaparib 150 mg twice daily dosing that was adjusted for his renal function. At the time of this writing, the patient experienced disease stability for 5 mo with Olaparib, which is ongoing. He tolerates Olaparib with grade 1 fatigue but has no major side effects. He is on regular monthly follow-ups.

DISCUSSION

Case series

Population and clinical data: We treated 11 PACC patients between August 2014 and July 2021 at Princess Margaret Cancer Centre (PMCC), Toronto. These comprised 6 (55%) pure and 5 (45%) mixed PACC. Approximately 2000 pancreatic carcinoma patients were managed at PMCC during this period. The median age at diagnosis of the PACC patients was 65 years (range 57-74) and all were male. At diagnosis, 2 (18%) were resectable, 2 (18%) locally advanced, and 7 (64%) metastatic. The full demographic features of all patients are summarized in Table 1.

Four (36%) patients had curative-intent surgery. Three of them developed systemic relapse and received subsequent treatment with palliative chemotherapy. All seven metastatic patients had chemotherapy. Altogether, ten patients received palliative chemotherapy: mFFX (6), GnP (3), and Gemcitabine (1).

The median time to progression from the date of surgery to the first systemic relapse for the resected patients was 10.5 mo (1.5-10.6). After a follow-up period of 20.4 mo, 6 (55%) patients had died of the disease while five are still alive. The median overall survival (OS) of the cohort was 20.4 mo (range 4.6-36.0) but this variable is temporally immature. The median OS of the four resected patients was 30.3 mo (28.2-36.0).

Genomic data: Eligibility for germline genetic testing in Ontario has evolved with the advent of next-generation sequencing, newly identified genes, and the association of established genes with different cancer types. In April 2021, Ontario Health expanded the availability of germline testing to all individuals with pancreatic cancer regardless of age or family history. (5) Before this, germline testing for individuals with pancreatic cancer was based on personal and family history as well as the age of onset. The gene(s) or multi-gene panels performed for patients are based on the individuals' personal and family history at the time of the initial genetic counseling.

Seven patients in our case series had clinical germline testing. Four patients did not have germline testing, as they did not meet eligibility criteria based on family history at the time of their diagnosis. Germline PV/LPV was identified in four patients [2 *BRCA2* (18%), 1 *ATM* (9%), 1 *CDKN2A* (9%)]. Two (18%) patients had somatic testing with whole-genome sequencing and RNA sequencing as part of clinical trial participation. Identified somatic variants were *SND1-BRAF* fusion in one patient and *KRAS*, *SMAD4*, *CDKN2A*, *ATM*, *TP53*, *TGFBR2*, and *KDM6A* in another patient.

In terms of actionability, we identified two patients with *BRCA2* PV/LPV (18%) and one *SND1-BRAF* fusion (9%). The first patient carrying a germline *BRCA2* LPV is described in this case report. The second patient carrying a germline *BRCA2* PV had advanced acinar neuroendocrine carcinoma. Briefly, he was commenced on a

combination of 5 FU and Oxaliplatin with a dose reduction (30%) due to comorbidities. Despite this, the evaluation CT scan following 8 cycles of chemotherapy showed a partial response of the primary tumor (63% smaller than baseline) as per RECIST1.1. He continued additional 4 cycles with further tumor regression, followed by resection. The tumor was pathologic near complete treatment response.

The patient harboring an *SND1-BRAF* fusion was commenced on first line GnP. The evaluation CT scans following 6 cycles of chemotherapy showed a significant partial response (55% decrease than baseline) of the primary tumor and lymph nodes as per RECIST1.1. After 16 cycles of GnP, he developed progressive disease and was switched to single-agent Cobimetinib as part of clinical trial participation. Molecular profiling was negative for other key driver mutations *KRAS*, *TP53*, *CDKN2A*, *SMAD4*, and *BRCA* in this patient. Full mutational profiles of the patients and treatment history are outlined in Table 2.

PACC typically presents in the younger population with a median age of 62 years old. It is more frequent in males, with a male-to-female ratio of 2.3:1^[6-8]. The majority (50%-60%) present at an advanced stage, with a median tumor size of 7 cm, and lesions smaller than 2 cm are rarely detected^[6-10]. Some cases present with mixed differentiation including mixed acinar-ductal and mixed acinar-neuroendocrine subtypes. As the tumor is predominantly found in the tail of the pancreas, patients do not usually present with biliary obstruction, and elevation of CA19-9 is not typically seen^[3,11]. However, there have been reports of elevated alpha-fetoprotein in younger patients^[7,8]. In extreme cases, up to 10%, of patients have lipase hypersecretion which leads to systemic fat necrosis with eosinophilia, erythematous subcutaneous nodules, and polyarthralgia^[6,7,9,10]. This paraneoplastic syndrome, also known as Schmid's triad, is often associated with a poor prognosis^[12-15]. The prognosis of PACC is slightly better than that for PDAC^[6]. In comparison, 5-year OS for PACC was 42.8% *vs* PDAC 3.8%^[16]. In this study, we analyzed the full clinical characteristics, therapeutic outcome and mutational signatures of 11 patients with PACC treated at our center. Based on our

analysis, the median OS across all stages is 20.4 mo and 30.3 mo among the resected patients.

Available literature suggests that over one-third of PACC patients harbor potentially druggable alterations such as *BRCA2*, *PALB2*, *ATM*, *BRAF*, and *JAK1*^[17]. We observed only one PACC with somatic *KRAS* mutation (9%). This result may be limited by the incomplete somatic testing rate in this study. In distinction to PDAC which is associated with *KRAS* driver mutations in more than 93% of cases, *KRAS* mutations occur at a much lower prevalence in the acinar/mixed neuroendocrine tumor (9%)^[18-21]. While it is difficult to generalize as pancreatic carcinoma is a complex heterogeneous disease, a strong argument can be made that the lack of mutated *KRAS* identifies a cohort rich in targetable alterations including fusions, and should have access to integrative germline and somatic sequencing^[22].

Multiple studies including a large series reported by Chmielecki *et al*^[2] involving 44 PACCs reported a 45% deficiency of DDR pathway genes^[3,4,23]. These are inclusive of deficiencies in the *BRCA* pathway and mismatch repair. Combined results suggested that approximately 23% of PACCs are enriched with fusion rearrangements involving *BRAF* or *RAF1* genes^[2,19]. It appears that PACC subgroups that are lacking *RAF1* rearrangements (*i.e.*, fusion-negative tumors) were significantly enriched for deficiency in HRD, and both tumor types are mutually exclusive^[2]. Conceptually, these “fusion-negative” tumors can serve as a beneficial demarcation in over two-thirds of PACC patients who may be candidates for platinum-based chemotherapy. PACC with *BRCA1/2* variants have greater sensitivity to platinum-based chemotherapy and demonstrate significantly better OS than when treated with non-platinum agents^[24]. Platinum chemotherapy drugs exert their cytotoxic effect by binding directly to DNA, causing crosslinking of DNA strands and thereby inducing DNA double-strand breaks, which also are ineffectively repaired in cells lacking functioning *BRCA1/2*. Both the patients in our case series with germline *BRCA2* PV/LPV had substantial radiographic regression with mFFX, despite dose reduced Oxaliplatin. Although our patient described in the case report was very unwell with poor PS at presentation, raising the

question of suitability for mFFX, the knowledge of the *BRCA2* LPV as predictive for platinum sensitivity guided our decision to use this regime which resulted in his improved outcome. The other patient was successfully downsized to enable the Whipple procedure for curative intent. Notably, we identified one patient with *SND1-BRAF* kinase fusion in our case series. Germline and somatic testing were negative for *BRCA1* or *BRCA2* in this patient. This particular variant fusion joins *SND1* exons 1-10 with *BRAF* exons 11-18 and maintains the reading frame. It is worth noting that this particular configuration is the most prevalent gene fusion described in melanoma, thyroid, and lung cancers. It has also been reported in PACC^[2]. This novel fusion is potentially targetable with MEK inhibitors, such as Trametinib and Cobimetinib^[2,25].

Germline testing and tumor sequencing results are invaluable in identifying PACC patients for treatment regime determination and predictive biomarkers for investigational targeted therapies^[14,22,23,26,27]. Newly diagnosed patients with PACC should undergo germline genetic testing and somatic profiling where appropriate, given the high frequency of pathogenic germline *BRCA* alterations in PACC. This should be made available to patients regardless of clinical presentation, the pattern of metastases, and pre-existing co-morbidities. This is also consistent with NCCN American Society of Clinical Oncology guidelines which recommend all PDAC patients have upfront germline testing as part of the evolving precision strategy and screening strategies^[28]. Similar to numerous studies, our patients with pathogenic *BRCA1/2* variants have an increased risk of pancreatic, ovarian, breast, and other cancers (Table 2). The lifetime risk for pancreatic cancer in *BRCA1* and *BRCA2* mutant carriers is 1% and 4.9%, respectively^[29,30]. Unlike breast and ovarian cancers, germline *BRCA1/2* mutations alone do not pose a significant risk of pancreatic cancers. Recent literature review shows *BRCA2* confer to 5%-17% of familial pancreatic cancers (FPC) and *BRCA1* is not as highly prevalent^[31-34]. Studies show that germline susceptibility gene mutations were not found in 80% of pancreatic cancer individuals with strong family history^[31,35]. Therefore, comprehensive genome sequencing is needed to identify new possible deleterious genes associated with FPC.

There are no current clinical practice algorithms for PACC, and it is treated in the same way as PDAC. Although FOLFIRINOX represents the standard treatment with the highest efficacy in PDAC, it is not well studied in PACC^[36]. Since 2010, there is a recognized OS benefit to platinum-based agents compared to Gemcitabine or Capecitabine-based regimens, and current therapeutic approaches of metastatic PACCs utilize more FOLFOX or FOLFIRINOX. Furukawa *et al*^[37] described a PACC patient with a *BRCA2* PV who received Cisplatin after a recurrence of liver metastasis and had a complete remission of the recurring tumor. Ploquin *et al*^[38] reported a PACC patient with a *BRCA2* PV who experienced a 14-year complete remission following nine cycles of GEMOX, without surgical intervention. Therefore, Cisplatin and GEMOX may be alternatives in patients harboring deficiencies in DDR genes who are unfit for FOLFIRINOX.

Due to accumulative neurotoxicity after 11 cycles of mFFX, our patient decided to stop systemic chemotherapy completely and de-escalated to Olaparib as a maintenance approach. The use of PARPi in PACC patients with germline *BRCA1* or *BRCA2* PV/LPV is anecdotal^[2,23,26]. Furthermore, the updated analysis of the POLO trial showed a lack of OS benefit and quality of life improvement in their Olaparib-treated patients compared to the placebo arm^[39]. Despite the aforementioned, we believe that metastatic PACC patients with confirmed HRD phenotype and demonstrated strictly defined platinum sensitivity that involved exceptional response after 16 wk of chemotherapy should be considered for the benefit of PARPi, as the case described.

Like PDAC, surgery offers the best treatment approach for improved long-term survival^[11,16,40]. The combination of surgical approach and perioperative chemotherapy in PACC is mainly adapted from the PDAC practice^[40-42]. As mentioned, our patient with metastatic germline *BRCA2* PV had remarkable tumor downstaging following mFFX, underwent curative surgery, and achieved a pathologic near complete treatment response. Optimizing treatment approaches from this standpoint, with growing access to germline and somatic profiling, should also be further explored in PACC.

CONCLUSION

Although it is a rare disease, it is important to identify both common and rare actionable variants in PACCs. In PACC patients with *BRCA* variants, the maintenance treatment of PARPi after effective platinum-based chemotherapy should be explored further. Surgical resection may provide the chance of cure after induction chemotherapy in very well-selected patients, particularly in patients with *BRCA* variants. Further large-scale studies are required to verify these therapeutic strategies for PACC patients.